Currently out of the existing stock ratings of Elliot Wilbur, 109 are a BUY (87.2%), 16 are a HOLD (12.8%).

Elliot Wilbur

Work Performance Price Targets & Ratings Chart

Analyst Elliot Wilbur, carries an average stock price target met ratio of 47.59% that have a potential upside of 36.48% achieved within 387 days. Previously, Elliot Wilbur worked at RAYMOND JAMES.

Elliot Wilbur’s has documented 207 price targets and ratings displayed on 24 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ADMA, ADMA Biologics at 07-May-2025.

Wall Street Analyst Elliot Wilbur

Analyst best performing recommendations are on PTX (PERNIX THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for PTX (PERNIX THERAPEUTICS HOLDINGS) at 11/13/2013. The price target of $50 was fulfilled within 127 days with a profit of $25.8 (106.61%) receiving and performance score of 8.39.

Average potential price target upside

of $44.92 (33.04%) on AGN (ALLERGAN PLC).
of $41.84 (74.86%) on SLGL (SOL GEL TECHNOLOGIES LTD).
of $25.47 (65.06%) on PTX (PERNIX THERAPEUTICS HOLDINGS).

ADMP Adamis Pharma AGN Allergan plc AKRX Akorn ANIP ANI Pharmaceuticals ATRS Antares Pharma FLXN Flexion Therapeutics MNK Mallinckrodt plc MYL Viatris PLXP PLx Pharma PRGO Perrigo Company PLC PTX Pernix Therapeutics Holdings SGNT Sagent Pharmaceuticals SLGL Sol Gel Technologies Ltd TEVA Teva Pharma Industries Ltd ADR ADMA ADMA Biologics AMRX Amneal Pharmaceuticals, Common Stock CVET Covetrus PETQ PetIQ PYPD PolyPid VTRS Viatris ZTS Zoetis AERI Aerie Pharmaceuticals AMPH Amphastar P OGN Organon

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jason Mccarthy (MAXIM GROUP)